BACKGROUND: Between 2007 and 2013, the Tanzanian public sector received 93.1 million doses of first-line anti-malarial artemisinin-based combination therapy (ACT) in the form of artemether-lumefantrine entirely supplied by funding partners.
mHealth Evidence is expanding to include grey literature in the growing body of evidence.
Registered users of mHealth Evidence may now use this bookmarklet feature to contribute material for submission. Please note contributors must be logged in to access this feature. All submissions will be reviewed.